Thrombosis is an indication for drug development with over 140 pipeline drugs currently active. According to GlobalData, preregistered drugs for Thrombosis have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Thrombosis compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Thrombosis

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Thrombosis overview

Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. This clot can obstruct the normal blood flow, potentially leading to various health complications. Thrombosis can occur in both veins and arteries. Common types include Deep Vein Thrombosis (DVT), where clots form in deep veins, often in the legs, and Pulmonary Embolism (PE), which occurs when a clot dislodges and travels to the lungs. Risk factors for thrombosis include immobility, surgery, certain medical conditions, and genetic factors. Treatment may involve anticoagulant medications to prevent clot formation, and in severe cases, interventions like thrombectomy or placement of a filter in the blood vessel may be considered.

For a complete picture of PTSR and LoA scores for drugs in Thrombosis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.